DUBLIN–(BUSINESS WIRE)–The “Glaucoma Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This Pharmaceutical and Healthcare pipeline guide, Glaucoma Pipeline Review, H1 2020 provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 20, 11, 3, 66, 18 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 3 molecules, respectively.
Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered
- Introduction
- Glaucoma – Overview
- Glaucoma – Therapeutics Development
- Glaucoma – Therapeutics Assessment
- Glaucoma – Companies Involved in Therapeutics Development
- Glaucoma – Drug Profiles
- Glaucoma – Dormant Projects
- Glaucoma – Discontinued Products
- Glaucoma – Product Development Milestones
- Appendix
Companies Mentioned
- AC Immune SA
- Aerie Pharmaceuticals Inc
- Aerpio Pharmaceuticals Inc
- Allergan Plc
- Amgen Inc
- Annexon Inc
- Asha Vision LLC
- Betaliq Inc
- Better Life Pharmaceuticals Inc
- Bial – Portela & Ca SA
- BioAxone BioSciences Inc
- Biozeus Pharmaceutical SA
- Califia Bio Inc
- Calpain Therapeutics Pty Ltd
- Cellix Bio Pvt Ltd
- Certa Therapeutics Pty Ltd
- Chong Kun Dang Pharmaceutical Corp
- D. Western Therapeutics Institute Inc
- Deha Pharmaceutical LLC
- Dhp Korea Ltd
- Disarm Therapeutics Inc
- Dompe Farmaceutici SpA
- Emerald Bioscience Inc
- Emerald Organic Products Inc
- Envisia Therapeutics Inc
- Evotec SE
- EyePoint Pharmaceuticals Inc
- Eyevensys SAS
- Fortress Biotech Inc
- Future Medicine Co Ltd
- Galimedix Therapeutics Ltd
- Gene Signal International SA
- Glaukos Corp
- Graybug Vision Inc
- Guangzhou Cellprotek Pharmaceutical Co Ltd
- Guangzhou Magpie Pharmaceutical Co Ltd
- Gurus BioPharm
- Handok Inc
- HitGen LTD
- ID Pharma Co Ltd
- Ildong Pharmaceutical Co Ltd
- InMed Pharmaceuticals Inc
- Inspyr Therapeutics Inc
- Isarna Therapeutics GmbH
- Kedalion Therapeutics Inc
- Kodiak Sciences Inc
- Kowa Co Ltd
- Kukje Pharmaceutical Industry Co Ltd
- Kyoto Drug Discovery & Development Co Ltd
- Laboratoires Thea SA
- Laboratorios SALVAT SA
- Laboratorios Sophia SA de CV
- LayerBio Inc
- Lee’s Pharmaceutical Holdings Ltd
- Matrix Biomed Inc
- MimeTech Srl
- MyX Therapeutics Inc
- Nanoscope Therapeutics Inc
- NeuBase Therapeutics Inc
- NeurAegis Inc
- Neurim Pharmaceuticals Ltd
- Neurizon Pharma GBR
- Neuroptika Inc
- NeuroScientific Biopharmaceuticals Ltd
- NicOx SA
- NoNO Inc
- Novaliq GmbH
- Novartis AG
- Noveome Biotherapeutics Inc
- Novoron Bioscience Inc
- Ocular Therapeutix Inc
- Oculo Therapy LLC
- Ocuphire Pharma Inc
- Oncolys BioPharma Inc
- ONL Therapeutics Inc
- Palo BioFarma SL
- pH Pharma Co Ltd
- Profarma
- Q BioMed Inc
- Qlaris Bio Inc
- Quark Pharmaceuticals Inc
- Qurgen Inc (Inactive)
- Radikal Therapeutics Inc
- ReNetX Bio
- Ripple therapeutics Corp
- Santen Pharmaceutical Co Ltd
- Stuart Therapeutics Inc
- Sun Pharma Advanced Research Company Ltd
- Sustained Nano Systems LLC
- Sylentis SAU
- TaeJoon Pharmaceuticals Co Ltd
- Takeda Pharmaceutical Co Ltd
- Teraclon IDF SL
- TikoMed AB
- Toa Eiyo Ltd
- Topadur Pharma AG
- ViSci Ltd
- Whitecap Biosciences LLC
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/zihe14
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900